Method of testing gastrointestinal diseases associated with species of genus clostridium

Abstract

The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate the microbial agent. The antimicrobial composition in a form of probiotic mixture can be administrated alone or in combination with an antimicrobial agent, such as a bacteriophage which is specific for a bacterium producing toxin or antibiotics which are then used to eliminate or inhibit the clostridial species overgrown in a patient's gastrointestinal tract. Disorders that can be treated by the method of the invention include diarrhea or inflammatory bowel diseases such as colitis or Crohn's disease.

1 . A method of treating gastrointestinal diseases associated with species of genus Clostridium in human, comprising: 
 determining that a patient has an etiological component such as a microbial agent producing a toxin;    administrating to said patient suffering therefrom an antimicrobial composition effective against species of genus Clostridium in an amount effective for treating said diseases;    wherein the antimicrobial composition is a probiotic agent comprising at least one of the bacterial species is a normal, benign inhabitant of a human gut.    
     
     
         2 . The method of  claim 1 , wherein said species of genus Clostridium is  Clostridium dificite  or  Clostridium tetani  strains.  
     
     
         3 . The method of claims  1  and  2 , wherein said gastrointestinal diseases associated with Clostridium species are diarrhea and inflammatory bowel diseases taken from the group consisting of ulcerative colitis, Crohn's disease, Parkinson's disease, Whipple's disease and d-lactic acidosis.  
     
     
         4 . The method of  claims 1  to  3 , wherein said probiotic agent is selected from the group consisting of  Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides distasonis, Bacteroides fragilis, Bifidobacterium adolescentis  group,  Eubacterium aerofaciens, Clostridium ramosum, Escherichia coli , and  Streptococcus faecalis  group, and mixtures thereof.  
     
     
         5 . The method of  claims 1  to  4 , wherein the antimicrobial composition is in the form of a tablet or capsule which is enteric coated.  
     
     
         6 . A method of treating a patient having a gastrointestinal diseases associated with species of genus Clostridium, comprising: 
 determining that a patient has an etiological component such as microbial agent producing a toxin;    administrating to said patient an antimicrobial agent for temporary eliminating or suppressing of said patient flora and thereafter administering to said patient a probiotic agent.    
     
     
         7 . The method of  claim 6 , wherein said species of Clostridium is  Clostridium dificite  or  Clostridium tetani  strains  
     
     
         8 . The method of claims  6  and  7 , wherein said gastrointestinal diseases associated with Clostridium are diarrhea and inflammatory bowel diseases such as ulcerative colitis, and Crohn's disease.  
     
     
         9 . The method of  claims 6  to  8 , wherein said probiotic mixture is selected from a group of species consisting of  Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides distasonis, Bacteroides fragilis, Bifidobacterium adolescentis  group,  Eubacterium aerofaciens, Clostridium ramosum, Escherichia coli , and  Streptococcus faecalis  group, and mixtures thereof.  
     
     
         10 . The method of  claims 6  to  9 , wherein the antimicrobial agent is a bacteriophage which is specific for a bacterium producing the disease.  
     
     
         11 . The method of  claim 10 , wherein the bacteriophage is administered in a form of an enterically coated tablet or capsule.  
     
     
         12 . The method of  claims 6  to  11 , wherein said antimicrobial agent is an antibiotic selected from a group consisting of ABT-773, Ampicillin/sulbactam, Amphomycin, Azithromycin, Bacitracin, Carbomycin, Cephalosporins, oral, Clarithromycin, Erythromycins, Furazolidone, Fusidic acid, Na fusidate, Gramicidin, Imipenem, oral, Josamycin, Linezolid, Macrolides, Metronidazole, Mikamycin, Novobiocin, Oleandomycin, triacetyloleandomycin, Ostreogrycin, Piperacillin/tazobactam, Pristinamycin, Ramoplanin, Ristocetin, Rosamiein, rosaramicin, Spectinomycin, Spiramycin, Staphylomycin, Streptogramin, Synergistin, Teicoplanin, Telithromycin, Ticarcillin/clavulanic acid, Trocidin, Tyrothricin, Vancomycin, Vernamycin, Virginiamycin, Amoxicillin/clavulnate and combinations thereof.  
     
     
         13 . The method of  claims 1  to  12 , wherein said probiotic agent consists of one or more of the following normal inhabitants of the human intestinal tract: any species of Bacteroides, Prevotella, Porphyromonas, Fusobacterium, Sutterella, Bilophila, Campylobacter, Wolinella, Butyrovibrio, Megamonas, Desulfomonas, Desulfovibrio, Bifidobacterium, Lactobacillus, Eubacterium, Actinomyces, Eggerthella, Coriobacterium, Propionibacterium, Bacillus, Peptostreptococcus (and newly created genera originally in Peptostreptococcus), Peptococcus, Acidaminococcus, Ruminococcus, Megasphaera, Gaffkya, Coprococcus, Veillonella, Sarcina, certain of the species of Clostridium, any of the species of the following genera: Aerococcus, Streptococcus, Enterococcus, Pediococcus, Micrococcus, Staphylococcus, Corynebacterium, and species of the genera comprising the Enterobacteriaceae and Pseudomonadaceae and mixtures thereof.  
     
     
         14 . The method of  claims 1  to  7 , wherein the antimicrobial agent is radionuclide.